Leadartis will be presenting its business proposal at the AseBio Investor Day (https://asebioevents.com/investorday/presenting-companies/) to be held on September 28-October 1^st. AseBio Investor Day is the leading event allowing Spanish innovative biotechnology projects to be presented to an audience of leading international investors and pharmaceutical & industrial companies. The event is organized by AseBio, the Spanish Bioindustry Association.

The novel coronavirus SARS-CoV-2 has recently emerged as a human pathogen in China, causing fever, severe respiratory illness, and pneumonia a disease recently named coronavirus disease 19 (COVID-19).

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes) funded Spanish Ministry of Science, Innovation and Universities (MICINN) under the RETOS 2017 Collaboration program. ATTACK counts with collaborators such as the internationally regarded: Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid and Centro Nacional de Investigaciones Oncológicas (CNIO).

LeadArtis and collaborators have published in the highly regarded scientific journal Nature Communications a new tactic to generate a tumor-targeted bispecific antibody to target a particularly relevant immune receptor, 4-1BB, which can activate cancer killer T-cells to erradicate tumors.